PMID- 30347815
OWN - NLM
STAT- MEDLINE
DCOM- 20190115
LR  - 20220325
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 19
IP  - 10
DP  - 2018 Oct 20
TI  - Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary 
      Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
LID - 10.3390/ijms19103258 [doi]
LID - 3258
AB  - Medullary thyroid cancer (MTC) is a rare malignancy with a poor prognosis. First 
      line therapy is surgery, which is the only curative method of the disease. 
      However, in non-operable cases or with tumor progression and metastases, a 
      systemic treatment is necessary. This form of cancer is often insensitive to 
      conventional chemotherapy, but the use of tyrosine kinase inhibitors (TKIs), such 
      as pazopanib, cabozantinib, and vandetanib, has shown promising results with an 
      increase in progression-free survival and prolonged lifetime. Therefore, we 
      focused on the pharmacological characteristics of TKIs, their mechanism of 
      action, their application as a secondary treatment option for MTC, their efficacy 
      as a cancer drug treatment, and reviewed the ongoing clinical trials. TKIs also 
      act systemically causing various adverse events (AEs). One common AE of this 
      treatment is hypertension, known to be associated with cardiovascular disease and 
      can therefore potentially worsen the well-being of the treated patients. The 
      available treatment strategies of drug-induced hypertension were discussed. The 
      mechanism behind the development of hypertension is still unclear. Therefore, the 
      treatment of this AE remains symptomatic. Thus, future studies are necessary to 
      investigate the link between tumor growth inhibition and hypertension. In 
      addition, optimized, individual treatment strategies should be implemented.
FAU - Milling, Rikke Vilsboll
AU  - Milling RV
AD  - Department of Biomedicine, Aarhus University, 8000 Aarhus C, Denmark. 
      rikke-milling@hotmail.com.
FAU - Grimm, Daniela
AU  - Grimm D
AD  - Department of Biomedicine, Aarhus University, 8000 Aarhus C, Denmark. 
      dgg@biomed.au.dk.
AD  - Clinic and Policlinic for Plastic, Aesthetic and Hand Surgery, 
      Otto-von-Guericke-University, 39120 Magdeburg, Germany. dgg@biomed.au.dk.
FAU - Kruger, Marcus
AU  - Kruger M
AUID- ORCID: 0000-0003-1120-0246
AD  - Clinic and Policlinic for Plastic, Aesthetic and Hand Surgery, 
      Otto-von-Guericke-University, 39120 Magdeburg, Germany. 
      marcus.krueger@med.ovgu.de.
FAU - Grosse, Jirka
AU  - Grosse J
AD  - Department of Nuclear Medicine, University of Regensburg, 95053 Regensburg, 
      Germany. jirka.grosse@klinik.uni-regensburg.de.
FAU - Kopp, Sascha
AU  - Kopp S
AD  - Clinic and Policlinic for Plastic, Aesthetic and Hand Surgery, 
      Otto-von-Guericke-University, 39120 Magdeburg, Germany. sascha.kopp@med.ovgu.de.
FAU - Bauer, Johann
AU  - Bauer J
AD  - Max-Planck Institute of Biochemistry, 82152 Martinsried, Germany. 
      jbauer@biochem.mpg.de.
FAU - Infanger, Manfred
AU  - Infanger M
AD  - Clinic and Policlinic for Plastic, Aesthetic and Hand Surgery, 
      Otto-von-Guericke-University, 39120 Magdeburg, Germany. 
      manfred.infanger@med.ovgu.de.
FAU - Wehland, Markus
AU  - Wehland M
AD  - Clinic and Policlinic for Plastic, Aesthetic and Hand Surgery, 
      Otto-von-Guericke-University, 39120 Magdeburg, Germany. 
      markus.wehland@med.ovgu.de.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181020
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Anilides)
RN  - 0 (Indazoles)
RN  - 0 (Piperidines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Pyrimidines)
RN  - 0 (Quinazolines)
RN  - 0 (Sulfonamides)
RN  - 1C39JW444G (cabozantinib)
RN  - 7RN5DR86CK (pazopanib)
RN  - YO460OQ37K (vandetanib)
RN  - Thyroid cancer, medullary
SB  - IM
MH  - Anilides/*adverse effects/therapeutic use
MH  - Carcinoma, Neuroendocrine/*drug therapy
MH  - Cardiotoxicity/etiology
MH  - Humans
MH  - Hypertension/*etiology
MH  - Indazoles
MH  - Piperidines/*adverse effects/therapeutic use
MH  - Protein Kinase Inhibitors/*adverse effects/therapeutic use
MH  - Pyridines/*adverse effects/therapeutic use
MH  - Pyrimidines/*adverse effects/therapeutic use
MH  - Quinazolines/*adverse effects/therapeutic use
MH  - Sulfonamides/*adverse effects/therapeutic use
MH  - Thyroid Neoplasms/*drug therapy
PMC - PMC6214082
OTO - NOTNLM
OT  - VEGF
OT  - antiangiogenesis
OT  - hypertension
OT  - medullary thyroid carcinoma
OT  - tyrosine kinase inhibitors
COIS- The authors declare no conflict of interest.
EDAT- 2018/10/24 06:00
MHDA- 2019/01/16 06:00
PMCR- 2018/10/01
CRDT- 2018/10/24 06:00
PHST- 2018/08/31 00:00 [received]
PHST- 2018/09/19 00:00 [revised]
PHST- 2018/10/17 00:00 [accepted]
PHST- 2018/10/24 06:00 [entrez]
PHST- 2018/10/24 06:00 [pubmed]
PHST- 2019/01/16 06:00 [medline]
PHST- 2018/10/01 00:00 [pmc-release]
AID - ijms19103258 [pii]
AID - ijms-19-03258 [pii]
AID - 10.3390/ijms19103258 [doi]
PST - epublish
SO  - Int J Mol Sci. 2018 Oct 20;19(10):3258. doi: 10.3390/ijms19103258.